For a better user experience please update your browser or use Chrome or Firefox browser.
Pomôcky
Publication detail
HomeOpinion on Benzophenone-3 (CAS No 131-57-7, EC No 205-031-5)
Metaúdaje publikácie
1. In light of the data provided and taking under consideration the concerns related to potential endocrine disrupting properties of Benzophenone-3, does the SCCS consider Benzophenone-3 safe when used as a UV-filter in cosmetic products up to a maximum concentration of 6% and up to 0.5% in cosmetic products to protect product formulation? On the basis of safety assessment, and considering the concerns related to potential endocrine disrupting properties of benzophenone-3 (BP-3), the SCCS has concluded that: a. The use of BP-3 as a UV-filter up to a maximum concentration of 6% in sunscreen products, either in the form of body cream, sunscreen propellant spray or pump spray, is not safe for the consumer. b. The use of BP-3 as a UV-filter up to a maximum concentration of 6% in face cream, hand cream, and lipsticks is safe for the consumer. c. The use of BP-3 up to 0.5% in cosmetic products to protect the cosmetic formulation is safe for the consumer. 2. Alternatively, what is according to the SCCS the maximum concentration considered safe for use of Benzophenone-3 as a UV-filter in cosmetic products? In the SCCS’s opinion, the use of BP-3 as a UV filter in the following sunscreen products is safe for the consumer up to a maximum concentration of: d. 2.2% in body creams, in propellant sprays and in pump sprays, provided that there is no additional use of BP-3 at 0.5% in the same formulation for protecting the cosmetic formulation. e. Where BP-3 is also used at 0.5% in the same formulation, the levels of BP-3 used as UV filter should not exceed 1.7% in body creams, in propellant sprays and in pump sprays. 3. Does the SCCS have any further scientific concerns with regard to the use of Benzophenone-3 in cosmetic products? It needs to be noted that the SCCS has regarded the currently available evidence for endocrine disrupting properties of BP-3 as inconclusive, and at best equivocal. This applies to all of the available data derived from in silico modelling, in vitro tests and in vivo studies, either considered individually or taken together. The SCCS considers that, whilst there are indications from some studies to suggest that BP-3 may have endocrine effects, the overall evidence is not conclusive enough at present for the SCCS to ascertain whether or not BP-3 is an ED substance, and this warrants further investigations. The SCCS mandates do not address environmental aspects. Therefore, this assessment did not cover the safety of BP-3 for the environment.
- Dátum uverejnenia:
- Kolektiv autorov: Generálne riaditeľstvo pre zdravie a bezpečnosť potravín (Európska komisia)
- Témy Zdravie spotrebiteľov
- Oblasť: analytická chémia , bezpečnosť výrobku , endokrinný disruptor , kozmetický produkt , ochrana spotrebiteľa , právne predpisy o chemických látkach , toxická látka , vedecká správa , zdravotnícka politika
|
PDF
|
|||
| ISSN 1831-4767 | ISBN 978-92-76-54757-0 | DOI 10.2875/102562 | Katalógové číslo EW-AQ-22-007-EN-N |
- Released on EU publications website:
Prehliadač dokumentov
Note:
Publikáciu nie je možné zobraziť v prehliadači dokumentov. Otvoriť webovú verziu
Prístup získate kliknutím na: Stiahnutie a jazykové verzie